A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
about
Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaSequence of treatment in locally advanced and metastatic renal cell carcinomaImmunotherapy for metastatic renal cell carcinoma.Renal cell carcinoma.MicroRNA-142-5p promotes cell growth and migration in renal cell carcinoma by targeting BTG3Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective AnalysisDifferential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma.Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma.Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale"Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular CarcinomaNivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.Axitinib in sequential therapy in metastatic renal cell carcinoma.Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line.Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.Treatment of elderly patients with metastatic renal cell carcinoma.Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review.Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN.Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways.Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma.The landscape of systematic reviews in urology (1998 to 2015): an assessment of methodological quality.Raised preoperative international normalised ratio (INR) identifies patients at high risk of perioperative death after simultaneous renal and cardiac surgery for tumours involving the peri-diaphragmatic inferior vena cava and right atrium.Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale?Preoperative serum-gamma-glutamyltransferase (GGT) does not represent an independent prognostic factor in a European cohort of patients with non-metastatic renal cell carcinoma.Tumor-initiating cells contribute to radiation resistance in primary human renal clear cell carcinomas by activating the DNA damage checkpoint response.Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study.Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma.28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC.Survival outcomes of double- and triple-sequential targeted therapy in patients with metastatic renal cell carcinoma: a retrospective comparison.Orellanine specifically targets renal clear cell carcinoma.Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
P2860
Q26766240-3A6C6E35-DB59-40AB-9683-03BF4CF36157Q26773653-7CFF92C9-DE74-4B38-849F-36BB2F8BA461Q30234458-C14C37FA-07C8-46B8-86E7-37483AE3BCE6Q30235364-FCD7FEBB-BF5E-47AC-8568-0D17F14D5C08Q33733228-78BFB2A3-DF21-4BCA-92B8-FD896CB3CF8BQ35985736-4F005593-E492-4403-9A10-A31532CDB395Q36132720-AE87C610-EBF0-47E6-8C65-1C8790BDF935Q36250654-2F54736D-06EA-45F8-8E9F-F72B8F4868FBQ36530958-5ADD4803-41B7-498E-A363-8CC0D34A3BFBQ37218304-89366620-BDEF-41A0-A269-9434132B12CDQ37245796-7FF481C6-EDA0-475F-9F2A-805F92D83302Q37264931-7710983E-72FE-4523-A743-9AC52CFD8DBDQ37290050-30B3B3AF-1E5F-4E1E-B0A9-5F78FA0184B9Q37527224-D86226CF-4141-4035-A706-4E6DDA667A7AQ37727634-5B72CCA9-BD29-4008-AB15-13B3510DB4A3Q38624864-C899CDE9-429C-4C9A-B781-69C5D09EFF5AQ38656760-A457BD8C-BCF7-4881-AAE2-C5CF016FF35DQ38657787-0EBCAA2E-696F-468D-99EE-53B1529167ADQ38665322-EC93C73C-B25E-4C86-ABFE-056B6091CF89Q38681585-08056F60-C8E0-41DF-B464-09D20B1996D6Q38699390-DF35F7A6-A054-4170-AD41-2CCC289B5D17Q38822454-51D22A47-EC51-415F-86DC-C9325886F2D7Q38860651-18F91AF6-73A4-4E16-B99C-17A795F23AB9Q38860807-847FC449-1804-41A0-AE88-A4696A60A1C3Q38889724-4ED57798-02FC-43B4-9C82-8DEACDD7AD67Q39120161-4D0AD761-62D7-4721-943B-ED428E28BA8FQ39138898-B3035980-33A0-43A9-A21E-03FEC7920561Q39406932-3A7C666E-F8C6-469C-B835-E539296ED9C7Q39588486-09FDEB69-45B9-4EED-B99E-0BCD1BE42C22Q39848776-9580F39D-9A5C-47DF-83D7-ABA598DB56C0Q41089343-AB27F45C-0B2F-4C04-B2E1-E8A9BDDC95DBQ41618207-E086D19C-CFD9-4299-8F7D-585153980E80Q41637603-5C61DB5B-4039-4344-BC9D-3BC68A4BE02AQ41920336-B17618E8-693B-4435-A334-7F494144626DQ42288643-A6E173A4-B352-4277-8089-67C954EB7B5EQ43182512-6A64B43C-E52D-4128-9D74-D876EDC63908Q47134616-5EA47C0C-18FF-4A26-8CE7-94DBBBF9093CQ47161748-C4149249-A44F-402A-B6ED-D7A7BB3A810EQ47265255-2A798D4B-09D9-4242-8641-3D31932C1C47Q47600932-19E3F556-8B86-4EF7-BC4A-94509F19395D
P2860
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A systematic review of sequenc ...... py in metastatic renal cancer.
@ast
A systematic review of sequenc ...... py in metastatic renal cancer.
@en
type
label
A systematic review of sequenc ...... py in metastatic renal cancer.
@ast
A systematic review of sequenc ...... py in metastatic renal cancer.
@en
prefLabel
A systematic review of sequenc ...... py in metastatic renal cancer.
@ast
A systematic review of sequenc ...... py in metastatic renal cancer.
@en
P2093
P1433
P1476
A systematic review of sequenc ...... py in metastatic renal cancer.
@en
P2093
Camillo Porta
Cora Sternberg
Dan George
Fabian Hofmann
Laurence Albiges
Matthew Galsky
Peter Mulders
Robert Motzer
Thomas Lam
P304
P356
10.1016/J.EURURO.2014.04.006
P407
P577
2014-05-01T00:00:00Z